Biodesix expects significant sales growth in third quarter
BOULDER — Biodesix Inc. (Nasdaq: BDSX), a Boulder-headquartered life-sciences company that specializes in developing tools to detect lung disease, is projecting third quarter 2022 revenues of $10.6 million to $11.2 million, up 62% to 71% compared to the same period last year.
The firm, which recently leased the entirety of an 80,000-square-foot former Kohl’s Corp. (NYSE: KSS) clothing store in Louisville to expand its operations, credits growth in its core lung diagnostic testing offerings with the improved results.
By year end, Biodesix expects to reach the high end of the range of its previously disclosed total revenue guidance for 2022 of…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…
